Compare · MIRM vs NVS
MIRM vs NVS
Side-by-side comparison of Mirum Pharmaceuticals Inc. (MIRM) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MIRM and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $284.62B, about 49.9x MIRM ($5.70B).
- Over the past year, MIRM is up 94.7% and NVS is up 24.7% - MIRM leads by 70.0 points.
- MIRM has hit the wire 14 times in the past 4 weeks while NVS has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Mirum Pharmaceuticals Inc.
- Novartis AG
- Price
- $91.66-2.00%
- $147.14-1.29%
- Market cap
- $5.70B
- $284.62B
- 1M return
- -10.99%
- +1.15%
- 1Y return
- +94.69%
- +24.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 14
- 0
- Recent ratings
- 25
- 25
Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest MIRM
- Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
- Director Cardon Lon converted options into 3,977 shares, increasing direct ownership by 70% to 9,680 units (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Peetz Christopher exercised 30,000 shares at a strike of $2.94 and sold $2,875,103 worth of shares (30,000 units at $95.84) as part of a pre-agreed trading plan (SEC Form 4)
- Director Walbert Timothy P converted options into 3,977 shares, increasing direct ownership by 70% to 9,680 units (SEC Form 4)
- Director Fischer Laurent converted options into 3,977 shares, increasing direct ownership by 59% to 10,727 units (SEC Form 4)
- Director Ramasastry Saira converted options into 3,977 shares and sold $397,700 worth of shares (3,977 units at $100.00) as part of a pre-agreed trading plan (SEC Form 4)
- Citigroup initiated coverage on Mirum Pharmaceuticals with a new price target
- SEC Form 144 filed by Mirum Pharmaceuticals Inc.
- SEC Form 144 filed by Mirum Pharmaceuticals Inc.
- Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG
- SEC Form 20-F filed by Novartis AG
- Citigroup initiated coverage on Novartis AG